Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Hollestelle, Martine J ^a   Lai, Ka Wai ^a   van Deuren, Marcel ^b   Lenting, Peter J ^a,c   de Groot, Philip G ^a   Sprong, Tom ^b   Bovenschen, Niels ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN; GRANZYME; GRANZYME M; LEUCINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; HEMOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENINGOCOCCEMIA; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING; THROMBOCYTE AGGREGATION; BLOOD; MENINGOCOCCOSIS; METABOLISM; MICROBIOLOGY; NEISSERIA MENINGITIDIS; PHYSIOLOGY; SEPTIC SHOCK; THROMBOCYTE;

BLOOD PLATELETS; COLLAGEN; FACTOR VIII; GRANZYMES; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PLATELET AGGREGATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SHOCK, SEPTIC; VON WILLEBRAND FACTOR;

EID: 80052342947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024216     Document Type: Article

References (43)

1. Ruggeri ZM, (1999) Structure and function of von Willebrand factor. Thromb Haemost 82: 576-584.
2. Weiss HJ, Sussman II, Hoyer LW, (1977) Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 60: 390-404.
3. Ruggeri ZM, (2003) Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1: 1335-1342.
4. Gao W, Anderson PJ, Sadler JE, (2008) Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 112: 1713-1719.
5. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488-494.
6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, et al. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339: 1578-1584.
7. Groot E, Fijnheer R, Sebastian SA, de Groot PG, Lenting PJ, (2009) The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. J Thromb Haemost 7: 962-969.
8. Desch KC, Motto DG, (2007) Thrombotic thrombocytopenic purpura in humans and mice. Arterioscler Thromb Vasc Biol 27: 1901-1908.
9. Mannucci PM, Lombardi R, Lattuada A, Ruggenenti P, Vigano GL, et al. (1989) Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood 74: 978-983.
10. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, et al. (2009) Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 114: 1666-1674.
11. Tsai HM, Nagel RL, Hatcher VB, Sussman II, (1989) Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases. Biochem Biophys Res Commun 158: 980-985.
12. Buzza MS, Dyson JM, Choi H, Gardiner EE, Andrews RK, et al. (2008) Antihemostatic activity of human granzyme B mediated by cleavage of von Willebrand factor. J Biol Chem 283: 22498-22504.
13. Chowdhury D, Lieberman J, (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 26:389-420.: 389-420.
14. Buzza MS, Bird PI, (2006) Extracellular granzymes: current perspectives. Biol Chem 387: 827-837.
15. Bade B, Lohrmann J, ten Brinke A, Wolbink AM, Wolbink GJ, et al. (2005) Detection of soluble human granzyme K in vitro and in vivo. Eur J Immunol 35: 2940-2948.
16. Hollestelle MJ, Sprong T, Bovenschen N, de Mast Q, van der Ven AJ, et al. (2010) Von Willebrand factor activation, granzyme-B and thrombocytopenia in meningococcal disease. J Thromb Haemostasis.
17. Chamberlain CM, Granville DJ, (2007) The role of Granzyme B in atheromatous diseases. Can J Physiol Pharmacol 85: 89-95.
18. Choy JC, McDonald PC, Suarez AC, Hung VH, Wilson JE, et al. (2003) Granzyme B in atherosclerosis and transplant vascular disease: association with cell death and atherosclerotic disease severity. Mod Pathol 16: 460-470.
19. Sodetz JM, Pizzo SV, McKee PA, (1977) Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem 252: 5538-5546.
20. Bovenschen N, de Koning PJ, Quadir R, Broekhuizen R, Damen JM, et al. (2008) NK cell protease granzyme M targets alpha-tubulin and disorganizes the microtubule network. J Immunol 180: 8184-8191.
21. Bovenschen N, Quadir R, van den Berg AL, Brenkman AB, Vandenberghe I, et al. (2009) Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. J Biol Chem 284: 3504-3512.
22. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, et al. (2005) A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 106: 3035-3042.
23. Weeterings C, de Groot PG, Adelmeijer J, Lisman T, (2008) The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 112: 3227-3233.
24. van der Plas RM, Gomes L, Marquart JA, Vink T, Meijers JC, et al. (2000) Binding of von Willebrand factor to collagen type III: role of specific amino acids in the collagen binding domain of vWF and effects of neighboring domains. Thromb Haemost 84: 1005-1011.
25. Goldstein B, Giroir B, Randolph A, (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6: 2-8.
26. de Koning PJ, Tesselaar K, Bovenschen N, Colak S, Quadir R, et al. (2010) The cytotoxic protease granzyme M is expressed by lymphocytes of both the innate and adaptive immune system. Mol Immunol 47: 903-911.
27. Dong JF, (2005) Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 3: 1710-1716.
28. Furlan M, Robles R, Lammle B, (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87: 4223-4234.
29. Tsai HM, (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87: 4235-4244.
30. De CR, Peyvandi F, Palla R, Lavoretano S, Lombardi R, et al. (2005) Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem 280: 23295-23302.
31. Groot E, de Groot PG, Fijnheer R, Lenting PJ, (2007) The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol 14: 284-289.
32. Spaeny-Dekking EH, Hanna WL, Wolbink AM, Wever PC, Kummer JA, et al. (1998) Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol 160: 3610-3616.
33. Froelich CJ, Pardo J, Simon MM, (2009) Granule-associated serine proteases: granzymes might not just be killer proteases. Trends Immunol 30: 117-123.
34. Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, et al. (2008) Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity 29: 720-733.
35. Sadler JE, (2002) A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci U S A 99: 11552-11554.
36. Mahrus S, Kisiel W, Craik CS, (2004) Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. J Biol Chem 279: 54275-54282.
37. Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, et al. (2006) Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem 281: 4699-4707.
38. Jorieux S, Gaucher C, Goudemand J, Mazurier C, (1998) A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization. Blood 92: 4663-4670.
39. Hilbert L, Jorieux S, Proulle V, Favier R, Goudemand J, et al. (2003) Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity. Br J Haematol 120: 627-632.
40. Banno F, Kokame K, Okuda T, Honda S, Miyata S, et al. (2006) Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 107: 3161-3166.
41. Kaiserman D, Bird CH, Sun J, Matthews A, Ung K, et al. (2006) The major human and mouse granzymes are structurally and functionally divergent. J Cell Biol %20 175: 619-630.
42. Cullen SP, Adrain C, Luthi AU, Duriez PJ, Martin SJ, (2007) Human and murine granzyme B exhibit divergent substrate preferences. J Cell Biol 176: 435-444.
43. van Woensel JB, Biezeveld MH, Hack CE, Bos AP, Kuijpers TW, (2005) Elastase and granzymes during meningococcal disease in children: correlation to disease severity. Intensive Care Med 31: 1239-1247.